These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 28293779

  • 1. Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol.
    Nakatoh S.
    J Bone Miner Metab; 2018 Mar; 36(2):221-228. PubMed ID: 28293779
    [Abstract] [Full Text] [Related]

  • 2. The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study.
    Nakatoh S.
    J Bone Miner Metab; 2016 Mar; 34(2):216-24. PubMed ID: 26031934
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Further significant effects of eldecalcitol on bone resorption markers and bone mineral density in postmenopausal osteoporosis patients having undergone long-term bisphosphonate treatment.
    Iba K, Sonoda T, Takada J, Dohke T, Yamashita T.
    J Bone Miner Metab; 2017 Mar; 35(2):171-176. PubMed ID: 26832388
    [Abstract] [Full Text] [Related]

  • 5. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K, Harigane K, Kusayama Y, Tezuka T, Choe H, Inaba Y, Saito T.
    Osteoporos Int; 2018 Jul; 29(7):1637-1642. PubMed ID: 29574518
    [Abstract] [Full Text] [Related]

  • 6. Minodronate in the treatment of osteoporosis: A systematic review and meta-analysis.
    Liu Q, Chen D, Ye Z, Jin Z, Ma T, Huang X.
    Medicine (Baltimore); 2020 Oct 02; 99(40):e22542. PubMed ID: 33019463
    [Abstract] [Full Text] [Related]

  • 7. Histological Effects of the Combined Administration of Eldecalcitol and a Parathyroid Hormone in the Metaphyseal Trabeculae of Ovariectomized Rats.
    Hasegawa T, Yamamoto T, Sakai S, Miyamoto Y, Hongo H, Qiu Z, Abe M, Takeda S, Oda K, de Freitas PHL, Li M, Endo K, Amizuka N.
    J Histochem Cytochem; 2019 Mar 02; 67(3):169-184. PubMed ID: 30311820
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the effects of 12 months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis.
    Ebina K, Noguchi T, Hirao M, Kaneshiro S, Tsukamoto Y, Yoshikawa H.
    J Bone Miner Metab; 2016 May 02; 34(3):243-50. PubMed ID: 26303222
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Short-term daily teriparatide in patients with rheumatoid arthritis.
    Kaneko T, Okamura K, Yonemoto Y, Okura C, Suto T, Tachibana M, Tamura Y, Inoue M, Chikuda H.
    Mod Rheumatol; 2018 May 02; 28(3):468-473. PubMed ID: 28805099
    [Abstract] [Full Text] [Related]

  • 11. Minodronate combined with alfacalcidol versus alfacalcidol alone for glucocorticoid-induced osteoporosis: a multicenter, randomized, comparative study.
    Soen S, Yamamoto K, Takeuchi T, Tanaka Y, Tanaka S, Ito M, Nakano T, Hagino H, Hirakawa A, Matsumoto T.
    J Bone Miner Metab; 2020 Jul 02; 38(4):511-521. PubMed ID: 31970477
    [Abstract] [Full Text] [Related]

  • 12. Effects of Teriparatide and Sequential Minodronate on Lumbar Spine Bone Mineral Density and Microarchitecture in Osteoporosis.
    Miyaoka D, Imanishi Y, Ohara M, Hayashi N, Nagata Y, Yamada S, Mori K, Emoto M, Inaba M.
    Calcif Tissue Int; 2017 Oct 02; 101(4):396-403. PubMed ID: 28589205
    [Abstract] [Full Text] [Related]

  • 13. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
    Mori Y, Kasai H, Ose A, Serada M, Ishiguro M, Shiraki M, Tanigawara Y.
    Osteoporos Int; 2018 May 02; 29(5):1155-1163. PubMed ID: 29423715
    [Abstract] [Full Text] [Related]

  • 14. Once-weekly teriparatide in hemodialysis patients with hypoparathyroidism and low bone mass: a prospective study.
    Sumida K, Ubara Y, Hoshino J, Mise K, Hayami N, Suwabe T, Kawada M, Imafuku A, Hiramatsu R, Hasegawa E, Yamanouchi M, Sawa N, Takaichi K.
    Osteoporos Int; 2016 Apr 02; 27(4):1441-1450. PubMed ID: 26525045
    [Abstract] [Full Text] [Related]

  • 15. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May 02; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 16. Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study.
    Matsumoto T, Hagino H, Shiraki M, Fukunaga M, Nakano T, Takaoka K, Morii H, Ohashi Y, Nakamura T.
    Osteoporos Int; 2009 Aug 02; 20(8):1429-37. PubMed ID: 19101754
    [Abstract] [Full Text] [Related]

  • 17. Bone turnover rate and bone formation/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change.
    Nakatoh S.
    Osteoporos Sarcopenia; 2017 Mar 02; 3(1):45-52. PubMed ID: 30775502
    [Abstract] [Full Text] [Related]

  • 18. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
    Mok J, Brown C, Moore AEB, Min SS, Hampson G.
    Endocr Res; 2018 Aug 02; 43(3):195-202. PubMed ID: 29652557
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of monthly oral minodronate in patients with involutional osteoporosis.
    Okazaki R, Hagino H, Ito M, Sone T, Nakamura T, Mizunuma H, Fukunaga M, Shiraki M, Nishizawa Y, Ohashi Y, Matsumoto T.
    Osteoporos Int; 2012 Jun 02; 23(6):1737-45. PubMed ID: 21932114
    [Abstract] [Full Text] [Related]

  • 20. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.
    Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH.
    J Clin Endocrinol Metab; 2009 Oct 02; 94(10):3772-80. PubMed ID: 19584192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.